Meeting
2019 Gastrointestinal Cancers Symposium
What is the role of the anti-angiogenic therapy in BRAF (V600E) mutant metastatic colorectal cancer patients in a real-world setting?
Authors
Nieves Martinez Lago
Medical Oncology Deparment - University Hospital A Coruña, A Coruña, Spain
Nieves Martinez Lago , Marta Covela Rúa , Elena Brozos Vazquez , Ana Fernandez Fernandez Montes , Juan Cruz De La Camara Gomez , Carlos Méndez Méndez , Mónica Jorge Fernández , Antia Cousillas Castiñeira , Begoña Graña Suárez , Guillermo Alfonso Quintero Aldana , Sonia Candamio Folgar , Mercedes Salgado Fernandez , Maria Luz Pellon Augusto , Paula Gonzalez Villarroel , Elena Gallardo Martin , Marta Carmona Campos , Francisca Vazquez Rivera , Carlos Grande Ventura , Alberto Carral Maseda , Margarita Reboredo Lopez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 620)
DOI
10.1200/JCO.2019.37.4_suppl.620
Abstract #
620
Poster Bd #
K5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Impact of circulating tumor DNA (ctDNA) mutant allele fraction in response to anti-angiogenic therapy in RAS-mutant metastatic colorectal cancer (mCRC): Clinical data in the first-line setting and correlation in patient-derived xenograft (PDX) models.
First Author: Nadia Saoudi Gonzalez
Poster
2022 ASCO Annual Meeting
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
First Author: Jean-Louis Legoux
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz